Best Weight-Loss Medications in 2026: A Complete Comparison

Weight-loss medication in 2026 looks nothing like it did five years ago. The arrival of GLP-1 receptor agonists has transformed what is medically possible, but these newer medications are not the only option — and for many patients, they are not the right starting point. This guide breaks down every major FDA-approved weight-loss medication available today, with honest information about efficacy, cost, side effects, and how to determine which one fits your situation.

What is available in 2026

There are more FDA-approved options for treating obesity and overweight than at any point in medical history. These medications fall into four main categories, each working through a different biological mechanism:

• GLP-1 and GIP/GLP-1 receptor agonists — Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). These injectable medications mimic gut hormones to reduce hunger, slow gastric emptying, and improve metabolic signaling. They represent the newest and most effective class.
• Sympathomimetic amines — Phentermine. The oldest and most widely prescribed weight-loss medication, working through norepinephrine to suppress appetite and increase energy expenditure.
• Combination medications — Contrave (naltrexone/bupropion). Targets both appetite and the brain’s reward pathways, addressing cravings and emotional eating patterns.
• Lipase inhibitors — Orlistat (Xenical/Alli). Blocks fat absorption in the gut rather than acting on the brain or hormonal systems.

The pipeline continues to expand. An oral formulation of semaglutide (Wegovy Pill) has received FDA approval for chronic weight management, offering a tablet alternative to the injectable form. Survodutide and retatrutide, next-generation multi-receptor agonists, are also in clinical trials showing promising early results. These may further expand available options in the coming years.

At PEAK, we evaluate every patient individually. The right medication is the one that matches your medical profile, your insurance reality, your budget, and your treatment goals. Sometimes that is a GLP-1. Sometimes it is phentermine. Sometimes it is a strategic combination. Let’s look at each option in detail.

GLP-1 and GIP/GLP-1 receptor agonist medications

GLP-1 and GIP/GLP-1 receptor agonists are the most significant advance in obesity pharmacotherapy in decades. These medications mimic a natural gut hormone called glucagon-like peptide-1, which plays a key role in appetite regulation, gastric motility, and insulin signaling. The result is a powerful reduction in hunger and food intake that most patients describe as a turning point.

Wegovy (semaglutide 2.4 mg)

Wegovy is a once-weekly subcutaneous injection and was the first GLP-1 approved specifically for chronic weight management. In the landmark STEP 1 trial, patients on semaglutide 2.4 mg lost an average of approximately 15% of their body weight over 68 weeks compared to about 2.4% with placebo. For a 250-pound patient, that translates to roughly 37 pounds of weight loss.

Wegovy requires a gradual dose escalation over 16–20 weeks, starting at 0.25 mg weekly and increasing to the maintenance dose of 2.4 mg. This titration schedule helps manage gastrointestinal side effects, which are most common during dose increases.

Zepbound (tirzepatide)

Zepbound is the newest and most effective weight-loss medication currently available. It is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin hormone pathways simultaneously. In the SURMOUNT-1 trial, patients on the highest dose (15 mg weekly) achieved an average weight loss of approximately 20–22% of body weight — among the highest efficacy of any currently FDA-approved anti-obesity medication.

Like Wegovy, Zepbound is a once-weekly injection with a dose escalation schedule. The dual-receptor mechanism appears to provide additional metabolic benefits beyond what GLP-1 activation alone can achieve.

Saxenda (liraglutide 3 mg)

Saxenda is the older generation GLP-1 medication for weight loss, requiring daily injections rather than weekly. Clinical trials showed approximately 8% average body weight loss — meaningful, but significantly less than the newer agents. Saxenda has been largely superseded by Wegovy and Zepbound in clinical practice, but it remains an option for patients who may respond better to liraglutide or who have specific insurance coverage for it.

Common side effects: Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects. These are typically most pronounced during dose escalation and tend to improve as the body adjusts. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid concerns (GLP-1s carry a boxed warning about medullary thyroid carcinoma based on animal studies).

Best for: Patients with BMI of 30 or above (or 27+ with weight-related comorbidities), who have insurance coverage or can afford the out-of-pocket cost, and who are looking for a long-term medication solution with the highest possible efficacy.

Phentermine

Phentermine has been FDA-approved since 1959 and remains the single most prescribed weight-loss medication in the United States. It is a sympathomimetic amine that works primarily by increasing norepinephrine levels in the brain, which suppresses appetite and provides a mild energy boost. Despite being more than six decades old, it continues to play an important role in modern obesity treatment.

Efficacy

Clinical studies show phentermine produces an average of 5–10% body weight loss over its typical prescribing period. While this is less than GLP-1 medications, it is clinically meaningful — a 5% weight loss can improve blood pressure, blood sugar, cholesterol, and reduce the risk of developing type 2 diabetes.

Cost and accessibility

Phentermine’s biggest advantage is accessibility. It is often the most affordable prescription weight-loss medication available. It is widely covered by insurance, widely available at pharmacies, and does not require prior authorization in most cases. For patients facing cost barriers, phentermine provides genuine clinical benefit at a fraction of the cost of newer options.

Limitations

Phentermine is FDA-approved for short-term use only, typically defined as up to 12 weeks. It is a Schedule IV controlled substance with stimulant properties, which means it can increase heart rate, elevate blood pressure, and cause insomnia. It is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, and certain other conditions.

Common side effects: Increased heart rate, elevated blood pressure, insomnia (especially if taken late in the day), dry mouth, and restlessness. These effects are related to its stimulant mechanism and are the primary reason it is limited to short-term use.

Best for: Patients looking for a short-term jump-start, those who need to complete step therapy before GLP-1 approval, cost-conscious patients, and those who are healthy enough to tolerate a sympathomimetic medication.

Contrave (naltrexone/bupropion)

Contrave is a combination of two well-established medications: naltrexone (an opioid antagonist used for addiction treatment) and bupropion (an antidepressant that also affects dopamine and norepinephrine). Together, they target the brain’s reward and appetite regulation pathways in a way that no other weight-loss medication does.

Efficacy

In the COR clinical trial program, Contrave produced an average of approximately 5–6% body weight loss compared to placebo. While this places it in the moderate efficacy range, Contrave’s real strength lies in its mechanism: it specifically addresses food cravings and the reward-driven eating patterns that many patients struggle with most.

Unique benefits

Contrave stands apart because of its impact on cravings and emotional eating. Naltrexone blocks opioid receptors involved in the pleasure response to food, while bupropion affects dopamine pathways that drive reward-seeking behavior. For patients whose weight gain is driven more by cravings, emotional eating, or binge eating patterns than by simple hunger, Contrave may be more effective in practice than its average trial numbers suggest.

Additionally, bupropion has antidepressant properties, which can be beneficial for patients dealing with mood issues alongside weight management. It is the only weight-loss medication that may simultaneously improve depressive symptoms.

Cost

Contrave typically costs $300–$400/month at retail, but the manufacturer offers a $99/month Home Delivery program and savings cards that can reduce copays to as little as $20/month. While there is no FDA-approved generic Contrave, some providers prescribe naltrexone and bupropion separately as a lower-cost off-label alternative. Contrave is generally more accessible than GLP-1 medications while providing a distinct mechanism of action.

Important safety information: Contrave carries a boxed warning regarding suicidal thoughts and behaviors associated with bupropion, particularly in younger adults. For a full breakdown, see our Contrave side effects guide. It should not be taken with opioid medications (naltrexone blocks opioid receptors), in patients with uncontrolled seizure disorders (bupropion lowers seizure threshold), or during abrupt discontinuation of alcohol or sedatives. These are important considerations your clinician will evaluate.

Common side effects: Nausea (most common, especially in the first few weeks), constipation, headache, dizziness, insomnia, and dry mouth. Nausea typically improves with continued use and can be managed by following the recommended dose titration schedule.

Best for: Patients with food cravings or emotional/binge eating patterns, those who also have depressive symptoms, patients who cannot tolerate or access GLP-1 medications, and those looking for an oral medication option with moderate efficacy and a unique mechanism.

Orlistat (Xenical / Alli)

Orlistat takes a fundamentally different approach from every other weight-loss medication on this list. Rather than working in the brain or through hormonal pathways, it acts locally in the gut by inhibiting pancreatic lipase — the enzyme responsible for breaking down dietary fat. The result is that approximately 30% of the fat you eat passes through unabsorbed.

Efficacy

Clinical trials show orlistat produces an average of 3–5% body weight loss. This is the lowest efficacy of the medications covered in this guide, but it remains a clinically validated option. The prescription strength (Xenical, 120 mg three times daily with meals) is more effective than the over-the-counter version (Alli, 60 mg).

Accessibility

Orlistat is unique in that it is available both as a prescription (Xenical) and over the counter (Alli). This makes orlistat one of the most accessible medication options overall.

The side effect tradeoff

Orlistat’s side effects are directly tied to dietary fat intake. If you eat a high-fat meal, the unabsorbed fat has to go somewhere — and the gastrointestinal consequences can be unpleasant. Oily or fatty stools, flatulence with discharge, fecal urgency, and increased bowel movements are common, particularly early in treatment or after high-fat meals. Some patients view this as a built-in behavioral feedback mechanism: the side effects naturally discourage high-fat eating.

Best for: Patients who prefer a non-systemic medication (orlistat does not enter the bloodstream in significant amounts), those who cannot take stimulants or centrally-acting medications due to medical conditions or preferences, patients who want an OTC option (Alli) as a starting point, and those with mild weight loss goals.

Head-to-head comparison

The following table summarizes the key differences between all major FDA-approved weight-loss medications available in 2026. Use this as a reference point, but remember that averages from clinical trials do not predict any individual patient’s response.

Note: Weight loss percentages are averages from clinical trials and reflect average total body weight loss in the active treatment arm of clinical trials. Individual results vary significantly. Monthly costs are approximate retail/generic pricing and may differ based on pharmacy, location, and manufacturer programs. PA = prior authorization.

How to choose the right medication

There is no single “best” weight-loss medication. The right choice depends on a combination of clinical factors, practical considerations, and personal preferences. Here is a framework for thinking through the decision.

Start with your goals and medical profile

Your BMI, existing health conditions, and weight loss goals form the clinical foundation. A patient with a BMI of 40 and type 2 diabetes has very different needs than a patient with a BMI of 28 looking to lose 20 pounds. The degree of weight loss needed, the urgency of weight-related health risks, and any contraindications all factor in.

Factor in insurance and budget

This is where reality meets clinical ideals. If your insurance covers Zepbound or Wegovy with a reasonable copay, a GLP-1 may be the clear first choice. If it does not, self-pay costs are often not sustainable for most patients. Lower-cost options like phentermine or Contrave (which offers a $99/month Home Delivery program) may deliver a better real-world outcome because you can afford to take them consistently.

Consider your eating patterns

Medications work differently depending on what drives your eating. If general hunger and portion sizes are the main challenge, GLP-1s and phentermine both address appetite effectively. If cravings, emotional eating, or reward-driven snacking are the primary issue, Contrave’s mechanism may be more targeted to your specific pattern. See how it compares in our Contrave vs. phentermine guide.

A practical decision framework

• Maximum weight loss + insurance covers it: GLP-1 medication (Zepbound or Wegovy)
• Cost-conscious + short-term start needed: Phentermine
• Cravings/emotional eating + moderate goals: Contrave
• Prefer non-systemic + mild weight loss: Orlistat
• Insurance requires step therapy: Phentermine first, then Contrave, then GLP-1 (this is the most common insurance-required pathway)

Frequently asked questions

What is the most effective weight-loss medication in 2026?

Tirzepatide (Zepbound) currently shows the highest efficacy in clinical trials, with average body weight loss of approximately 20–22% in the SURMOUNT trials. However, “most effective” also depends on what you can access, afford, and tolerate. A medication that you can actually take consistently will always outperform one you cannot access or cannot stay on due to side effects. Your clinician can help determine which option is most effective for your specific situation.

Can I take weight-loss medications long-term?

It depends on the medication. GLP-1 and GIP/GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda) and Contrave are all approved for long-term use. Orlistat can also be used long-term. Phentermine is the exception — it is FDA-approved for short-term use only, typically up to 12 weeks. Your clinician will help determine the appropriate duration based on your individual response and health profile.

Do I need a prescription for weight-loss medication?

All prescription weight-loss medications require a medical evaluation and prescription from a licensed provider. The only exception is Alli (orlistat 60 mg), which is available over the counter without a prescription. PEAK provides medical evaluations and prescriptions through both telehealth and in-person visits, making it convenient to get started with the right medication.

Will my insurance cover weight-loss medication?

Coverage varies widely by plan and by medication. Phentermine is almost universally covered and very affordable even without insurance. Contrave has moderate coverage and offers manufacturer savings programs including a $99/month Home Delivery option. GLP-1 medications like Wegovy and Zepbound often require prior authorization, and some plans exclude them entirely or require step therapy first. PEAK handles insurance verification and prior authorization on your behalf so you understand your coverage and costs before beginning treatment.

What happens when I stop taking weight-loss medication?

Weight regain after stopping medication is common, particularly with GLP-1s. Research has shown that approximately two-thirds of weight lost on semaglutide may be regained within a year of discontinuation. This is not a failure of the medication — it reflects the biology of obesity as a chronic condition. At PEAK, our approach includes lifestyle modification support alongside medication to build sustainable habits that help minimize rebound when medications are tapered or discontinued.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.